Decreased adherence to antiretroviral therapy observed prior to transient human immunodeficiency virus type 1 viremia
Decreased adherence to antiretroviral therapy observed prior to transient human immunodeficiency virus type 1 viremia
复制标题
DOI：
10.1086/523704
复制
发表时间：
2007-12-15
影响因子：
6.4
通讯作者：
Hanna, George J.
中科院分区：
文献类型：
--
作者：
Podsadecki, Thomas J.;Vrijens, Bernard C.;Hanna, George J.
背景资料。目的：确定血浆病毒载量一过性升高的潜在原因和临床意义。M99-056和M02-418是评估洛匹那韦/利托那韦(LPV/r)胶囊对人类免疫缺陷病毒-1(HIV-1)感染者每天两次或一次的安全性和有效性的前瞻性随机试验。每4周(从基线到24周，不包括M02-418的12周和20周)、每8周(从24周到48周)和每12周(从48周到96周)测定血浆病毒载量。BLIP的定义是：1测量血浆病毒载量在50-1000拷贝/毫升之间，紧接着在之前和之后测量
Background. To identify potential causes and clinical implications of transient increases in plasma viral load (hereafter, "blips").Methods. M99-056 and M02-418 were prospective, randomized trials evaluating the safety and efficacy of lopinavir/ ritonavir (LPV/r) capsules administered twice per day or once per day to subjects infected with human immunodeficiency virus-1 (HIV-1). Plasma viral load was measured every 4 weeks (from baseline through week 24, excluding week 12 and week 20 in M02-418), every 8 weeks (from week 24 through week 48), and every 12 weeks (from week 48 through week 96). Blips were defined by 1 plasma viral load measurement of between 50-1000 copies/mL, immediately preceded and immediately followed by a measurement of